Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys

Alice F Tarantal, Francesca Giannoni, C. Chang I Lee, Jennifer Wherley, Teiko Sumiyoshi, Michele Martinez, Christoph A. Kahl, David Elashoff, Stan G. Louie, Donald B. Kohn

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Immune responses to transgene products may lead to rejection of transduced cells, limiting successful gene therapy for genetic diseases. While moderate dosages of chemotherapeutic agents such as busulfan may increase hematopoietic stem cells (HSC) engraftment, they are not immune suppressive and do not abrogate immune responses to transgene products. Studies focused on nonmyeloablative conditioning with busulfan fludarabine in a clinically relevant monkey model to induce immune suppression to allow cells expressing a foreign transgene product to persist. Bone marrow CD34+ HSC were transduced in two equal fractions using simian immunodeficiency virus (SIV)-based lentiviral vectors carrying a nonexpressed DNA sequence tag (NoN) and the green fluorescent protein (GFP) reporter gene. Post-transplant there was no evidence of elimination of cells containing the potentially immunogenic GFP gene; several recipients had stable persistence of cells, and no differences were detected with fludarabine, which was rapidly cleared. Antibodies and cellular immune responses to GFP developed in recipients with the highest levels of GFP-marked cells, although these cells were not eliminated. These studies establish a clinically relevant pediatric primate model to assess the effects of conditioning regimens on the engraftment of transduced HSC and the immune responses to cells expressing a foreign gene product.

Original languageEnglish (US)
Pages (from-to)1033-1045
Number of pages13
JournalMolecular Therapy
Volume20
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Hematopoietic Stem Cells
Macaca mulatta
Green Fluorescent Proteins
Genes
Transgenes
Busulfan
Simian Immunodeficiency Virus
Inborn Genetic Diseases
Reporter Genes
Cellular Immunity
Genetic Therapy
Primates
Haplorhini
Bone Marrow
Pediatrics
Transplants
Antibodies

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys. / Tarantal, Alice F; Giannoni, Francesca; I Lee, C. Chang; Wherley, Jennifer; Sumiyoshi, Teiko; Martinez, Michele; Kahl, Christoph A.; Elashoff, David; Louie, Stan G.; Kohn, Donald B.

In: Molecular Therapy, Vol. 20, No. 5, 05.2012, p. 1033-1045.

Research output: Contribution to journalArticle

Tarantal, AF, Giannoni, F, I Lee, CC, Wherley, J, Sumiyoshi, T, Martinez, M, Kahl, CA, Elashoff, D, Louie, SG & Kohn, DB 2012, 'Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys', Molecular Therapy, vol. 20, no. 5, pp. 1033-1045. https://doi.org/10.1038/mt.2011.312
Tarantal, Alice F ; Giannoni, Francesca ; I Lee, C. Chang ; Wherley, Jennifer ; Sumiyoshi, Teiko ; Martinez, Michele ; Kahl, Christoph A. ; Elashoff, David ; Louie, Stan G. ; Kohn, Donald B. / Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys. In: Molecular Therapy. 2012 ; Vol. 20, No. 5. pp. 1033-1045.
@article{695f7c6370d842549c67d810aa5d41ac,
title = "Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys",
abstract = "Immune responses to transgene products may lead to rejection of transduced cells, limiting successful gene therapy for genetic diseases. While moderate dosages of chemotherapeutic agents such as busulfan may increase hematopoietic stem cells (HSC) engraftment, they are not immune suppressive and do not abrogate immune responses to transgene products. Studies focused on nonmyeloablative conditioning with busulfan fludarabine in a clinically relevant monkey model to induce immune suppression to allow cells expressing a foreign transgene product to persist. Bone marrow CD34+ HSC were transduced in two equal fractions using simian immunodeficiency virus (SIV)-based lentiviral vectors carrying a nonexpressed DNA sequence tag (NoN) and the green fluorescent protein (GFP) reporter gene. Post-transplant there was no evidence of elimination of cells containing the potentially immunogenic GFP gene; several recipients had stable persistence of cells, and no differences were detected with fludarabine, which was rapidly cleared. Antibodies and cellular immune responses to GFP developed in recipients with the highest levels of GFP-marked cells, although these cells were not eliminated. These studies establish a clinically relevant pediatric primate model to assess the effects of conditioning regimens on the engraftment of transduced HSC and the immune responses to cells expressing a foreign gene product.",
author = "Tarantal, {Alice F} and Francesca Giannoni and {I Lee}, {C. Chang} and Jennifer Wherley and Teiko Sumiyoshi and Michele Martinez and Kahl, {Christoph A.} and David Elashoff and Louie, {Stan G.} and Kohn, {Donald B.}",
year = "2012",
month = "5",
doi = "10.1038/mt.2011.312",
language = "English (US)",
volume = "20",
pages = "1033--1045",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys

AU - Tarantal, Alice F

AU - Giannoni, Francesca

AU - I Lee, C. Chang

AU - Wherley, Jennifer

AU - Sumiyoshi, Teiko

AU - Martinez, Michele

AU - Kahl, Christoph A.

AU - Elashoff, David

AU - Louie, Stan G.

AU - Kohn, Donald B.

PY - 2012/5

Y1 - 2012/5

N2 - Immune responses to transgene products may lead to rejection of transduced cells, limiting successful gene therapy for genetic diseases. While moderate dosages of chemotherapeutic agents such as busulfan may increase hematopoietic stem cells (HSC) engraftment, they are not immune suppressive and do not abrogate immune responses to transgene products. Studies focused on nonmyeloablative conditioning with busulfan fludarabine in a clinically relevant monkey model to induce immune suppression to allow cells expressing a foreign transgene product to persist. Bone marrow CD34+ HSC were transduced in two equal fractions using simian immunodeficiency virus (SIV)-based lentiviral vectors carrying a nonexpressed DNA sequence tag (NoN) and the green fluorescent protein (GFP) reporter gene. Post-transplant there was no evidence of elimination of cells containing the potentially immunogenic GFP gene; several recipients had stable persistence of cells, and no differences were detected with fludarabine, which was rapidly cleared. Antibodies and cellular immune responses to GFP developed in recipients with the highest levels of GFP-marked cells, although these cells were not eliminated. These studies establish a clinically relevant pediatric primate model to assess the effects of conditioning regimens on the engraftment of transduced HSC and the immune responses to cells expressing a foreign gene product.

AB - Immune responses to transgene products may lead to rejection of transduced cells, limiting successful gene therapy for genetic diseases. While moderate dosages of chemotherapeutic agents such as busulfan may increase hematopoietic stem cells (HSC) engraftment, they are not immune suppressive and do not abrogate immune responses to transgene products. Studies focused on nonmyeloablative conditioning with busulfan fludarabine in a clinically relevant monkey model to induce immune suppression to allow cells expressing a foreign transgene product to persist. Bone marrow CD34+ HSC were transduced in two equal fractions using simian immunodeficiency virus (SIV)-based lentiviral vectors carrying a nonexpressed DNA sequence tag (NoN) and the green fluorescent protein (GFP) reporter gene. Post-transplant there was no evidence of elimination of cells containing the potentially immunogenic GFP gene; several recipients had stable persistence of cells, and no differences were detected with fludarabine, which was rapidly cleared. Antibodies and cellular immune responses to GFP developed in recipients with the highest levels of GFP-marked cells, although these cells were not eliminated. These studies establish a clinically relevant pediatric primate model to assess the effects of conditioning regimens on the engraftment of transduced HSC and the immune responses to cells expressing a foreign gene product.

UR - http://www.scopus.com/inward/record.url?scp=84860542947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860542947&partnerID=8YFLogxK

U2 - 10.1038/mt.2011.312

DO - 10.1038/mt.2011.312

M3 - Article

VL - 20

SP - 1033

EP - 1045

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -